Granite Point Capital Management, L.P. Neu Base Therapeutics, Inc. Transaction History

Granite Point Capital Management, L.P.

  • $0
  • Q3 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 10, 2021
SELL
$3.27 - $4.76 $265,553 - $386,554
-81,209 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$4.63 - $7.34 $375,997 - $596,074
81,209 New
81,209 $389,000

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Granite Point Capital Management, L.P. Portfolio

Follow Granite Point Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Granite Point Capital Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email